Boceprevir, an NS3 Protease Inhibitor of HCV

Kenneth Berman, Paul Y. Kwo

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) is a major cause of chronic liver disease leading to death from liver failure or hepatocellular carcinoma. Hepatitis C is the most common indication for liver transplantation worldwide and is a major cause of the increased incidence of hepatocellular cancer in the United States. The current paradigm for HCV treatment relies on pegylated interferon and ribavirin as agents that enhance endogenous mechanisms for viral clearance and are dependent on host factors. In patients with genotype 1 HCV infection, sustained viral response (SVR) rates remain suboptimal, with less than half of genotype 1-infected individuals going on to achieve SVR. This has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. This review focuses on boceprevir, a protease inhibitor, and discusses its mechanism of action, effects on HCV, and viral resistance.

Original languageEnglish
Pages (from-to)429-439
Number of pages11
JournalClinics in Liver Disease
Volume13
Issue number3
DOIs
StatePublished - Aug 2009

Fingerprint

Protease Inhibitors
Hepacivirus
Genotype
Investigational Therapies
Ribavirin
Liver Failure
Virus Diseases
Liver Neoplasms
Hepatitis C
Liver Transplantation
Interferons
Antiviral Agents
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
hepatitis C virus NS3 protein
Liver Diseases
Hepatocellular Carcinoma
Chronic Disease
Incidence
Therapeutics

Keywords

  • HCV
  • Hepatitis C
  • Interferon
  • Protease
  • Resistance
  • Ribovirin
  • Stat-C

ASJC Scopus subject areas

  • Hepatology

Cite this

Boceprevir, an NS3 Protease Inhibitor of HCV. / Berman, Kenneth; Kwo, Paul Y.

In: Clinics in Liver Disease, Vol. 13, No. 3, 08.2009, p. 429-439.

Research output: Contribution to journalArticle

Berman, Kenneth ; Kwo, Paul Y. / Boceprevir, an NS3 Protease Inhibitor of HCV. In: Clinics in Liver Disease. 2009 ; Vol. 13, No. 3. pp. 429-439.
@article{e92625af91af47c593017841d5b5d5ce,
title = "Boceprevir, an NS3 Protease Inhibitor of HCV",
abstract = "Hepatitis C virus (HCV) is a major cause of chronic liver disease leading to death from liver failure or hepatocellular carcinoma. Hepatitis C is the most common indication for liver transplantation worldwide and is a major cause of the increased incidence of hepatocellular cancer in the United States. The current paradigm for HCV treatment relies on pegylated interferon and ribavirin as agents that enhance endogenous mechanisms for viral clearance and are dependent on host factors. In patients with genotype 1 HCV infection, sustained viral response (SVR) rates remain suboptimal, with less than half of genotype 1-infected individuals going on to achieve SVR. This has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. This review focuses on boceprevir, a protease inhibitor, and discusses its mechanism of action, effects on HCV, and viral resistance.",
keywords = "HCV, Hepatitis C, Interferon, Protease, Resistance, Ribovirin, Stat-C",
author = "Kenneth Berman and Kwo, {Paul Y.}",
year = "2009",
month = "8",
doi = "10.1016/j.cld.2009.05.008",
language = "English",
volume = "13",
pages = "429--439",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Boceprevir, an NS3 Protease Inhibitor of HCV

AU - Berman, Kenneth

AU - Kwo, Paul Y.

PY - 2009/8

Y1 - 2009/8

N2 - Hepatitis C virus (HCV) is a major cause of chronic liver disease leading to death from liver failure or hepatocellular carcinoma. Hepatitis C is the most common indication for liver transplantation worldwide and is a major cause of the increased incidence of hepatocellular cancer in the United States. The current paradigm for HCV treatment relies on pegylated interferon and ribavirin as agents that enhance endogenous mechanisms for viral clearance and are dependent on host factors. In patients with genotype 1 HCV infection, sustained viral response (SVR) rates remain suboptimal, with less than half of genotype 1-infected individuals going on to achieve SVR. This has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. This review focuses on boceprevir, a protease inhibitor, and discusses its mechanism of action, effects on HCV, and viral resistance.

AB - Hepatitis C virus (HCV) is a major cause of chronic liver disease leading to death from liver failure or hepatocellular carcinoma. Hepatitis C is the most common indication for liver transplantation worldwide and is a major cause of the increased incidence of hepatocellular cancer in the United States. The current paradigm for HCV treatment relies on pegylated interferon and ribavirin as agents that enhance endogenous mechanisms for viral clearance and are dependent on host factors. In patients with genotype 1 HCV infection, sustained viral response (SVR) rates remain suboptimal, with less than half of genotype 1-infected individuals going on to achieve SVR. This has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. This review focuses on boceprevir, a protease inhibitor, and discusses its mechanism of action, effects on HCV, and viral resistance.

KW - HCV

KW - Hepatitis C

KW - Interferon

KW - Protease

KW - Resistance

KW - Ribovirin

KW - Stat-C

UR - http://www.scopus.com/inward/record.url?scp=67650523017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650523017&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2009.05.008

DO - 10.1016/j.cld.2009.05.008

M3 - Article

C2 - 19628159

AN - SCOPUS:67650523017

VL - 13

SP - 429

EP - 439

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -